UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications

Annals of oncology, 2023-08, Vol.34 (8), p.693-702

2023

Volltextzugriff (PDF)

Corrigendum to ‘IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications’: [Annals of Oncology 34 (2023) p693-702]

Annals of oncology, 2024-05, Vol.35 (5), p.482-482

2024

Volltextzugriff (PDF)

Subcutaneous versus intravenous nivolumab for renal cell carcinoma

Annals of oncology, 2024-09

2024

Volltextzugriff (PDF)

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

Annals of oncology, 2024-11, Vol.35 (11), p.1026-1038

2024

Volltextzugriff (PDF)

Outcomes of breast cancer patients older than 80 years treated with adjuvant radiotherapy

European journal of cancer (1990), 2017-02, Vol.72, p.S27-S28

2017

Volltextzugriff (PDF)

696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial

Annals of oncology, 2020-09, Vol.31, p.S1159-S1159

2020

Volltextzugriff (PDF)

Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) dans le traitement de première ligne (1L) du carcinome rénal avancé (CCRa) : données de suivi à long terme de l’étude de phase 3 CheckMate 214

Progrès en urologie. Formation médicale continue, 2024-11, Vol.34 (7), p.S27-S27

2024

Volltextzugriff (PDF)

711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy

Annals of oncology, 2020-09, Vol.31, p.S559-S560

2020

Volltextzugriff (PDF)

Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial

ESMO open, 2024-05, Vol.9 (5), p.102994, Article 102994

2024

Volltextzugriff (PDF)

Survie conditionnelle et suivi à 5 ans dans l’étude checkmate 214 : Nivolumab + Ipilimumab (N+I) versus Sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (ACCR)

Progrès en urologie (Paris), 2021-11, Vol.31 (13), p.837-837

2021

Volltextzugriff (PDF)

Nivolumab + Cabozantinib (N+C) vs Sunitinib (S) en première ligne (1L) de traitement chez des patients atteints d’un carcinome rénal avancé (ACCR) dans l’essai de phase III checkmate 9ER : analyse en sous-groupes basée sur l’absence ou présence de néphrectomie antérieure

Progrès en urologie (Paris), 2021-11, Vol.31 (13), p.838-838

2021

Volltextzugriff (PDF)

Nivolumab + ipilimumab (N + I) vs sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (aRCC) dans l’étude CheckMate 214 : suivi à 4 ans et analyse en sous-groupe des patients (pts) non néphrectomisés

Progrès en urologie (Paris), 2020-11, Vol.30 (13), p.785-786

2020

Volltextzugriff (PDF)

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

The New England journal of medicine, 2021-03, Vol.384 (9), p.829-841

2021

Volltextzugriff (PDF)

ANG1005 for breast cancer brain metastases: correlation between 18F-FLT–PET after first cycle and MRI in response assessment

Breast cancer research and treatment, 2016-11, Vol.160 (1), p.51-59

2016

Volltextzugriff (PDF)

Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma

The New England journal of medicine, 2023-11, Vol.389 (19), p.1778-1789

2023

Volltextzugriff (PDF)

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma

The New England journal of medicine, 2023-05, Vol.388 (19), p.1767-1778

2023

Volltextzugriff (PDF)

213A - Outcomes of breast cancer patients older than 80 years treated with adjuvant radiotherapy

European journal of cancer (1990), 2017-02, Vol.72, p.S27-S28

2017

Volltextzugriff (PDF)

EP-1155: Outcomes of breast cancer patients older than 80 years treated with adjuvant radiotherapy

Radiotherapy and oncology, 2017-05, Vol.123, p.S628-S628

2017

Volltextzugriff (PDF)

319O ALTA-3: A randomized trial of brigatinib (BRG) vs alectinib (ALC) in crizotinib (CRZ)-refractory advanced ALK+ NSCLC

Annals of oncology, 2022-11, Vol.33, p.S1564-S1564

2022

Volltextzugriff (PDF)

1447P IMscin001 part 2 updated results: Efficacy, safety, immunogenicity and patient-reported outcomes (PROs) from the randomised phase III study of atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

Annals of oncology, 2023-10, Vol.34, p.S823-S823

2023

Volltextzugriff (PDF)

LBA53 Nivolumab (NIVO) plus relatlimab with platinum-doublet chemotherapy (PDCT) vs NIVO + PDCT as first-line (1L) treatment (tx) for stage IV or recurrent NSCLC: Results from the randomized phase II RELATIVITY-104 study

Annals of oncology, 2024-09, Vol.35, p.S1243-S1244

2024

Volltextzugriff (PDF)

1691P Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients (pts) with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Updated efficacy and safety results from CheckMate 67T

Annals of oncology, 2024-09, Vol.35, p.S1013-S1014

2024

Volltextzugriff (PDF)

Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma

The New England journal of medicine, 2024-08, Vol.391 (8), p.710

2024

Volltextzugriff (PDF)

1270P IMscin001: Phase Ib dose-finding study of subcutaneous atezolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

Annals of oncology, 2020-09, Vol.31, p.S820-S821

2020

Volltextzugriff (PDF)

LBA74 Final analysis of the phase III LITESPARK-005 study of belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC)

Annals of oncology, 2024-09, Vol.35, p.S1262-S1263

2024

Volltextzugriff (PDF)

1 – 25 von 75

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(73)
Mit Volltextzugriff
(73)

Publikationsform

Artikel
(74)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Subcutaneous versus intravenous nivolumab for renal cell carcinoma

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

Outcomes of breast cancer patients older than 80 years treated with adjuvant radiotherapy

696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial

Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) dans le traitement de première ligne (1L) du carcinome rénal avancé (CCRa) : données de suivi à long terme de l’étude de phase 3 CheckMate 214

711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy

Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial

Survie conditionnelle et suivi à 5 ans dans l’étude checkmate 214 : Nivolumab + Ipilimumab (N+I) versus Sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (ACCR)

Nivolumab + Cabozantinib (N+C) vs Sunitinib (S) en première ligne (1L) de traitement chez des patients atteints d’un carcinome rénal avancé (ACCR) dans l’essai de phase III checkmate 9ER : analyse en sous-groupes basée sur l’absence ou présence de néphrectomie antérieure

Nivolumab + ipilimumab (N + I) vs sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (aRCC) dans l’étude CheckMate 214 : suivi à 4 ans et analyse en sous-groupe des patients (pts) non néphrectomisés

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

ANG1005 for breast cancer brain metastases: correlation between 18F-FLT–PET after first cycle and MRI in response assessment

Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma

213A - Outcomes of breast cancer patients older than 80 years treated with adjuvant radiotherapy

EP-1155: Outcomes of breast cancer patients older than 80 years treated with adjuvant radiotherapy

319O ALTA-3: A randomized trial of brigatinib (BRG) vs alectinib (ALC) in crizotinib (CRZ)-refractory advanced ALK+ NSCLC

1447P IMscin001 part 2 updated results: Efficacy, safety, immunogenicity and patient-reported outcomes (PROs) from the randomised phase III study of atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

LBA53 Nivolumab (NIVO) plus relatlimab with platinum-doublet chemotherapy (PDCT) vs NIVO + PDCT as first-line (1L) treatment (tx) for stage IV or recurrent NSCLC: Results from the randomized phase II RELATIVITY-104 study

1691P Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients (pts) with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Updated efficacy and safety results from CheckMate 67T

Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma

1270P IMscin001: Phase Ib dose-finding study of subcutaneous atezolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

LBA74 Final analysis of the phase III LITESPARK-005 study of belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC)

Suchergebnisse filtern